TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia

Ibrutinib may revert the T-helper (Th)2 polarization observed in chronic lymphocytic leukemia (CLL) by targeting the IL-2-inducible kinase, that shows a significant homology with the Bruton tyrosine kinase. In the front-line GIMEMA LLC1114 trial (ibrutinib+rituximab for 6 months, followed by ibrutin...

Full description

Bibliographic Details
Main Authors:	Maria Cristina Puzzolo, Ilaria Del Giudice, Nadia Peragine, Paola Mariglia, Maria Stefania De Propris, Luca Vincenzo Cappelli, Livio Trentin, Gianluigi Reda, Antonio Cuneo, Stefano Molica, Alfonso Piciocchi, Valentina Arena, Francesca Romana Mauro, Anna Guarini, Robin Foà
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Oncology
Subjects:	chronic lymphocytic leukemia ibrutinib Th1 Th2 T lymphocytes
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.637186/full

Similar Items

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
by: Francesca Romana Mauro, et al.
Published: (2021-06-01)

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
by: Francesca Romana Mauro, et al.
Published: (2021-12-01)

Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017
by: Stefano Molica
Published: (2017-08-01)

Studying the Frequency Ratio of Treg/Th1 and Treg/Th2 Lymphocytes in Hodgkin\'s Lymphoma Patients and its Relationship with Disease Prognosis
by: N Arandi, et al.
Published: (2022-12-01)

Studying the Frequency Ratio of Treg/Th1 and Treg/Th2 Lymphocytes in Hodgkin\'s Lymphoma Patients and its Relationship with Disease Prognosis
by: N Arandi, et al.
Published: (2023-03-01)

IMBALANCE OF IMMUNOREGULATORY Th1- AND Th2-CYTOKINES IN PERSISTENT VIRAL INFECTIONS
by: I. O. Naslednikova, et al.
Published: (2014-07-01)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
by: Gianluigi Reda, et al.
Published: (2018-06-01)

Ibrutinib-Associated Leukocytoclastic Vasculitis in a Patient with Chronic Lymphocytic Leukemia
by: Ayşe Kaya, et al.
Published: (2024-03-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Isacco Ferrarini, et al.
Published: (2022-04-01)

İbrutinib Sonrası Gelişen Dev Ekimoz ve Hematom: Olgu Sunumu
by: Aynur Uğur Bilgin, et al.
Published: (2017-03-01)

EXPERIENCE WITH IBRUTINIB IN PATIENTS WITH REFRACTORY AND RECURRENT B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
by: T. V. SOROKINA, et al.
Published: (2017-06-01)

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors
by: Peter Georgantopoulos, et al.
Published: (2019-05-01)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
by: Alessandro Broccoli, et al.
Published: (2021-12-01)

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
by: Simon Schliffke, et al.
Published: (2018-04-01)

Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder
by: Daniel Rivera, et al.
Published: (2021-06-01)

Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell Transplant
by: Samip Master, et al.
Published: (2017-06-01)

Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia
by: Gülşen İskender, et al.
Published: (2020-08-01)

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data
by: Anıl Tombak, et al.
Published: (2021-12-01)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
by: Antonio Cuneo, et al.
Published: (2020-11-01)

Th1/Th2 cytokine production and reception features in Graves' disease
Published: (2012-06-01)

Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib
by: Anna Christoforidou, et al.
Published: (2018-05-01)

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
by: Jennifer A. Woyach, et al.
Published: (2023-01-01)

Expression and Clinical Significance of Th1/Th2/Th17 Cytokines and Lymphocyte Subsets in PCNSL
by: Bian H, et al.
Published: (2022-07-01)

Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature
by: Carolina Afonso, et al.
Published: (2022-10-01)

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study
by: Francesca Romana Mauro, et al.
Published: (2024-03-01)

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia
by: Federica Frezzato, et al.
Published: (2021-10-01)

Change in function of thl - and th2-lymphocytes and cytokine profile at chronic intoxication of ethanol
by: A.A. Svistunov, et al.
Published: (2010-06-01)

Isolated central nervous system Aspergillosis infection in a chronic lymphocytic leukemia patient on Ibrutinib: A case report
by: Thuy-Hong Le, et al.
Published: (2020-02-01)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
by: Maurizio Cavallari, et al.
Published: (2017-01-01)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
by: Yanyan Liu, et al.
Published: (2022-08-01)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
by: Benjamin Arthurs, MD, et al.
Published: (2017-01-01)

Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients
by: Natasa Kustrimovic, et al.
Published: (2018-07-01)

Behçet's disease‐like clinical manifestations of chronic lymphocytic leukemia during good response to ibrutinib
by: Kosuke Obama, et al.
Published: (2023-08-01)

Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study
by: Ann Janssens, et al.
Published: (2022-10-01)

Successful Management of Ibrutinib-Induced Thrombocytopenia in a Patient with Chronic Lymphocytic Leukemia: No Interruption, Only Reduction
by: Simge Erdem, et al.
Published: (2024-03-01)

An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib
by: Fady Gh Haddad, et al.
Published: (2021-01-01)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
by: Ayad M. Al‐Katib, et al.
Published: (2020-09-01)

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial
by: David E. Spaner, et al.
Published: (2019-04-01)

A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL
by: Can Chen, et al.
Published: (2023-03-01)